These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 23633399)
41. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. Sanoff HK; Sargent DJ; Green EM; McLeod HL; Goldberg RM J Clin Oncol; 2009 Sep; 27(25):4109-15. PubMed ID: 19636001 [TBL] [Abstract][Full Text] [Related]
42. Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial. Innominato PF; Ballesta A; Huang Q; Focan C; Chollet P; Karaboué A; Giacchetti S; Bouchahda M; Adam R; Garufi C; Lévi FA Cancer Med; 2020 Jun; 9(12):4148-4159. PubMed ID: 32319740 [TBL] [Abstract][Full Text] [Related]
43. Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patients. Chen Y; Wang Y; Shi Y; Dai G BMC Cancer; 2017 Apr; 17(1):242. PubMed ID: 28376763 [TBL] [Abstract][Full Text] [Related]
44. [Chrono-chemotherapy and dose intensity]. Lévi F Bull Cancer; 1995; 82 Suppl 1():29s-36s. PubMed ID: 7626851 [TBL] [Abstract][Full Text] [Related]
45. Chronotherapy with 5-fluorouracil, oxaliplatin, and folinic acid in colorectal cancer. Sandor V Lancet; 1997 Nov; 350(9087):1325-6. PubMed ID: 9357429 [No Abstract] [Full Text] [Related]
46. Home-Based e-Health Platform for Multidimensional Telemonitoring of Symptoms, Body Weight, Sleep, and Circadian Activity: Relevance for Chronomodulated Administration of Irinotecan, Fluorouracil-Leucovorin, and Oxaliplatin at Home-Results From a Pilot Study. Innominato P; Komarzynski S; Karaboué A; Ulusakarya A; Bouchahda M; Haydar M; Bossevot-Desmaris R; Mocquery M; Plessis V; Lévi F JCO Clin Cancer Inform; 2018 Dec; 2():1-15. PubMed ID: 30652550 [TBL] [Abstract][Full Text] [Related]
47. Pharmacoeconomic comparison between chronochemotherapy and FOLFOX regimen in the treatment of patients with metastatic colorectal cancer: a cost-minimization study. Tampellini M; Bitossi R; Brizzi MP; Saini A; Tucci M; Alabiso I; Dogliotti L Tumori; 2004; 90(1):44-9. PubMed ID: 15143971 [TBL] [Abstract][Full Text] [Related]
48. Pharmaco-economic comparative evaluation of combination chronotherapy vs. standard chemotherapy for colorectal cancer. Focan C Chronobiol Int; 2002 Jan; 19(1):289-97. PubMed ID: 11962682 [TBL] [Abstract][Full Text] [Related]
49. The circadian timing system in clinical oncology. Innominato PF; Roche VP; Palesh OG; Ulusakarya A; Spiegel D; Lévi FA Ann Med; 2014 Jun; 46(4):191-207. PubMed ID: 24915535 [TBL] [Abstract][Full Text] [Related]
51. Tumori. Chronotherapy Study Group of the European Organization for Research and Treatment of Cancer. Garufi C; Dogliotti L; Terzoli E; Focan C; Smaaland R; Chollet P; Perpoint B; Lévi F Tumori; 1999; 85(2):149-50. PubMed ID: 10363085 [No Abstract] [Full Text] [Related]
55. Old age: biologic versus chronologic. Gelibter AJ; Di Segni S; Zeuli M; Milella M; Ferretti G; Nuzzo C; Cognetti F J Clin Oncol; 2007 Feb; 25(6):e8. PubMed ID: 17308262 [No Abstract] [Full Text] [Related]
56. Bevacizumab for metastatic colon cancer: does patient BMI influence survival? Kaidar-Person O; Badarna H; Bar-Sela G Anticancer Drugs; 2015 Mar; 26(3):363-6. PubMed ID: 25563769 [TBL] [Abstract][Full Text] [Related]
57. Chronotherapy for cancer. Eriguchi M; Levi F; Hisa T; Yanagie H; Nonaka Y; Takeda Y Biomed Pharmacother; 2003 Oct; 57 Suppl 1():92s-95s. PubMed ID: 14572683 [TBL] [Abstract][Full Text] [Related]
58. Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer. Blauwhoff-Buskermolen S; Versteeg KS; de van der Schueren MA; den Braver NR; Berkhof J; Langius JA; Verheul HM J Clin Oncol; 2016 Apr; 34(12):1339-44. PubMed ID: 26903572 [TBL] [Abstract][Full Text] [Related]
59. Value of tumor size as a prognostic factor in metastatic colorectal cancer patients after chemotherapy: a population-based study. Yan Q; Zhang K; Guo K; Liu S; Wasan HS; Jin H; Yuan L; Feng G; Shen F; Shen M; Ma S; Ruan S Future Oncol; 2019 May; 15(15):1745-1758. PubMed ID: 31038364 [No Abstract] [Full Text] [Related]
60. Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Innominato PF; Focan C; Gorlia T; Moreau T; Garufi C; Waterhouse J; Giacchetti S; Coudert B; Iacobelli S; Genet D; Tampellini M; Chollet P; Lentz MA; Mormont MC; Lévi F; Bjarnason GA; Cancer Res; 2009 Jun; 69(11):4700-7. PubMed ID: 19470769 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]